Enzymatica: ColdZyme to be introduced in the UK

Regulatory information

Enzymatica, which develops and sells medical products based on enzyme from deep-sea cod, has signed an agreement with AHA Sales and Marketing for the distribution of the company's common cold product ColdZyme® Mouth Spray to pharmacies in the UK. Initially the product will be introduced in the pharmacy-led health and beauty retailer, Boots UK, starting in September 2014.

In conjunction with the launch Enzymatica will invest in a media campaign.

“We are very pleased to expand into the UK market. We thus meet one of our goals for 2014 - to launch ColdZyme in markets outside Scandinavia. The expansion to the UK demonstrates the scalability of our business model and our ability to reach out to new markets with our product. The fact that leading retailer Boots UK chooses to take in ColdZyme in its product range confirms the product's unique features and its competitive strength. I believe that we already next year will see the results of our efforts in this strategically important market”, says Michael Edelborg Christensen, CEO of Enzymatica.

The agreement also secures the support of AHA Sales and Marketing to market and sell ColdZyme Mouth Spray to all pharmacy chains in the UK. AHA will be responsible for marketing and sales as well as warehousing and delivery of ColdZyme.

In the UK, the value of OTC products in the cold category was approximately 945 million USD in 2012. Within the EU, the UK is one of the five largest markets in the category. ColdZyme will be available in all major Boots UK stores from September 2014.

For more information, please contact:
Michael Edelborg Christensen, CEO Enzymatica AB (publ),
Phone: +46 768 14 41 66. E-mail: michael.christensen@enzymatica.se 

About Enzymatica AB
Enzymatica AB (publ) develops and sells medical technology products based on an enzyme from deep-sea cod. Our development includes medical devices in upper respiratory infections and oral health, and veterinary products in oral health and dermatology. Its launched medical portfolio includes ColdZyme® CE Mouth spray for colds, available at the Swedish pharmacy market since 2013. It is headquartered in Lund, Sweden and is listed on Aktietorget.

About Boots UK
Boots UK is the leading pharmacy-led health and beauty retailer in the UK, with close to 2,500* Boots UK stores and over 60,000* employees. Boots UK’s purpose is to help customers look and feel better than they ever thought possible. Customers are at the heart of our business which is committed to providing exceptional customer and patient care, be the first choice for pharmacy and healthcare, offer innovative products 'only at Boots' such as the UK’s leading skincare brand No7, all delivered with the great value our customers love. Created over 160 years ago, the Boots brand is still at the heart of the communities it serves.

Boots UK is a member of Alliance Boots, a leading international, pharmacy-led health and beauty group delivering a range of products and services to customers. Working in close partnership with manufacturers and pharmacists, Alliance Boots is committed to improving health in the local communities it serves and helping its customers and patients to look and feel their best. Its focus is on growing its two core business activities of: pharmacy-led health and beauty retailing and pharmaceutical wholesaling and distribution. Alliance Boots has a presence in more than 25* countries and employs over 108,000* people. Alliance Boots has pharmacy-led health and beauty retail businesses in nine* countries and operates more than 3,150* health and beauty retail stores, of which just under 3,050* have a pharmacy.

*Figures are approximations as at 31 March 2014 and include associates and joint ventures.

Enzymatica cares about your privacy and processes your personal data in accordance with the EU’s General Data Protection Regulation. For more information about how we handle your personal information, and what rights you have, please refer to our personal data processing document here.